Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark T Esser

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Nature Communications|July 2, 2022
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strainsJames Brett Case, Samantha Mackin, John M Errico, et al.
Journal of Clinical Microbiology|June 27, 2022
Performance of the Cepheid Methicillin-Resistant Staphylococcus aureus/S. aureus Skin and Soft Tissue Infection PCR Assay on Respiratory Samples from Mechanically Ventilated Patients for S. aureus Screening during the Phase 2 Double-Blind SAATELLITE StudyAlexey Ruzin, Olivier Barraud, Li Yu, et al.
Mabs|December 8, 2022
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodiesAndrew Dippel, Austin Gallegos, Vineela Aleti, et al.
JAMA Network Open|April 26, 2023
Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical TrialsRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
Emerging Microbes & Infections|January 2, 2024
In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primatesAmi Patel, Kyle Rosenke, Elizabeth M Parzych, et al.
The Lancet. Infectious Diseases|April 24, 2021
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trialBruno François, Hasan S Jafri, Jean Chastre, et al.
BMC Infectious Diseases|June 28, 2020
Global molecular diversity of RSV - the "INFORM RSV" studyAnnefleur C Langedijk, Robert Jan Lebbink, Christiana Naaktgeboren, et al.
The Lancet. Oncology|May 3, 2005
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialLuisa L Villa, Ronaldo L R Costa, Carlos A Petta, et al.
Science Translational Medicine|January 25, 2022
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humansYueh-Ming Loo, Patrick M McTamney, Rosalinda H Arends, et al.
Nature Communications|October 6, 2022
DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2Elizabeth M Parzych, Jianqiu Du, Ali R Ali, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Nature Communications|July 2, 2022
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strainsJames Brett Case, Samantha Mackin, John M Errico, et al.
Journal of Clinical Microbiology|June 27, 2022
Performance of the Cepheid Methicillin-Resistant Staphylococcus aureus/S. aureus Skin and Soft Tissue Infection PCR Assay on Respiratory Samples from Mechanically Ventilated Patients for S. aureus Screening during the Phase 2 Double-Blind SAATELLITE StudyAlexey Ruzin, Olivier Barraud, Li Yu, et al.
Mabs|December 8, 2022
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodiesAndrew Dippel, Austin Gallegos, Vineela Aleti, et al.
JAMA Network Open|April 26, 2023
Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical TrialsRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
Emerging Microbes & Infections|January 2, 2024
In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primatesAmi Patel, Kyle Rosenke, Elizabeth M Parzych, et al.
The Lancet. Infectious Diseases|April 24, 2021
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trialBruno François, Hasan S Jafri, Jean Chastre, et al.
BMC Infectious Diseases|June 28, 2020
Global molecular diversity of RSV - the "INFORM RSV" studyAnnefleur C Langedijk, Robert Jan Lebbink, Christiana Naaktgeboren, et al.
The Lancet. Oncology|May 3, 2005
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialLuisa L Villa, Ronaldo L R Costa, Carlos A Petta, et al.
Science Translational Medicine|January 25, 2022
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humansYueh-Ming Loo, Patrick M McTamney, Rosalinda H Arends, et al.
Nature Communications|October 6, 2022
DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2Elizabeth M Parzych, Jianqiu Du, Ali R Ali, et al.
Pageof 10